Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sawai: Investment for Future Growth Cuts Profits Despite 28.9% Rise in Sales
June 11, 2007
- Given Imaging's Capsule Endoscope Spotlighted at JGES Meeting
June 11, 2007
- Trade-Off Concept Should Underlie New Pricing System: Dr Aoki
June 11, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 11, 2007
- Lack of Experienced CRAs Decelerates Growth of CRO Business: Mr Nakamura of CMIC
June 11, 2007
- Japan-Specific GCP Requirements Must Be Eliminated: SJP Seminar
June 11, 2007
- EPS to Aggressively Hire New Graduates
June 11, 2007
- R&D NEWS IN BRIEF
June 11, 2007
- Early Price Offering by Wholesalers Essential to Expedite Price Negotiation Process: Korosho
June 11, 2007
- REPORTER'S EYE／Incidence of NSAID-Induced Ulcers on the Rise in Japan
June 11, 2007
- Korosho Should Also Listen to Small Pharmacy Chains: Mr Kashiwagi
June 11, 2007
- Time to Launching of Anticancer Agents to Be Shortened by 2.5 Years: Korosho Council
June 11, 2007
- Further Efforts Needed to Improve Business Practices: Mr Matsutani
June 11, 2007
- SURVEY／Arrhythmia, Heart Disease Recognized as Risk Factors of Stroke by Only 40% of Japanese
June 11, 2007
- BUSINESS NEWS IN BRIEF
June 11, 2007
- REGULATORY NEWS IN BRIEF
June 11, 2007
- NHI Price Listing Recommended for 28 Products (13 APIs)
June 11, 2007
- Use Generics to Save Money and Use That Money to Increase Prices of New Drugs: Mr Hirate
June 11, 2007
- Cialis, TRAVATANZ Recommended for Approval
June 11, 2007
- Imiquimod, Garenoxacin Recommended for Approval
June 11, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…